Initiates Coverage on Neovasc (NASDAQ:NVCN)

Stock analysts at started coverage on shares of Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $125.00 price objective on shares of Neovasc in a research note on Friday, March 11th.

Shares of Neovasc stock opened at $6.05 on Wednesday. Neovasc has a 52-week low of $4.59 and a 52-week high of $23.50. The stock’s 50-day simple moving average is $9.54 and its 200 day simple moving average is $10.90. The stock has a market capitalization of $16.38 million, a P/E ratio of -0.50 and a beta of 2.48. The company has a debt-to-equity ratio of 0.27, a quick ratio of 12.50 and a current ratio of 12.88.

Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) last announced its quarterly earnings data on Thursday, May 12th. The medical equipment provider reported ($3.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.76). Neovasc had a negative net margin of 1,192.20% and a negative return on equity of 50.69%. The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.80 million. Equities research analysts forecast that Neovasc will post -5 EPS for the current fiscal year.

Neovasc Company Profile (Get Rating)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.

See Also

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.